News and Comments

Incyte Is a Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...

Dyax Acquisition and Biocryst Future

  Tuesday, November 03, 2015


Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015



  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Incyte And Merck Agree to Expand Their agreement Regarding their Immunotherapy Combination Drugs

  Tuesday, October 13, 2015


Yesterday Market Performance Brings Back Hope in Normalcy. Compugen Announced Some Encouraging News.

  Thursday, October 08, 2015

Stories From Yesterday Market More...

XOMA: A New Chance for Resurrection?

  Friday, October 02, 2015
  • - Exclusively licenses global rights to its (TGFb) antibody program to Novartis 
  •  More...

Recent Postings



Merck (MRK) KERYX (KERX) Sanofi (SNA) Sangamo (SGMO) Auspex (ASPX) Mirati Therapeutics (MRTX) ISIS (ISIS) SYNTA (SNTA) NANTKWEST (NK) Prosensa (RNA) Intrexon (XON) Abbott Laboratories (ABT) ARGOS (ARGS) Biocryst (BCRX) Cytokinetics (CYTK) VANDA (VNDA) REGULUS (RGLS) Roche (RHHBY) Bellicum (BLCM) IDERA (IDRA) Theravance (THRX) Theravance Bio Pharma (TBPH) Ziofpharm (ZIOP) Exelixis (EXEL) Sequenom (SQNM) Velcade (bortezomib) Regeneron (REGN) Roche (ROCHE) GlaxoSmithKline (GSK) Benlysta (belimumab) PTC Therapeutics (PTCT) Adaptimmune (ADAP) galapagos (GLPG) Seattle Genetics (SGEN) KITE (KITE) C4 Therapeutics AERIE PHARMACEUTICALS AstraZeneca (AZN) RenenxBio (RGNX) Tysabri Revlimid (lenolidamide) Gilead (GILD) Zerenex CompuGen (CGEN) Illumina (ILMN) Onyx (ONXX) ARCA (ABIO) Dendreon (DNDN) Endometrial Cancer Idenix (IDIX) Amgen (AMGN) Vitae Pharmaceuticals (VTAE) Elan (ELN) Rapamune CEMPRA (CEMP) LEXICON (LXRX) Human Genome Sciences (HGSI) Agenus (AGEN Valeant Pharmaceuticals International (VRX) Anacor (ANAC) Biogen Idec (BIIB) Global Cell Therapeutics (GBT) ABBVIE (ABBV) INNOVIVA (INVA) SERES THERAPEUTICS (MCRB) Pluristem (PSTI) Jazz Pharmaceuticals (JAZZ) SUNESIS PHARMACEUTICALS (SNSS) Anadys (ANDS) NEKTAR (NKTR)) Alnylam (ALNY) Trastuzumab-DM1 Ocular Therapeutix (OCUL) OncoCyte (OCX) HALOZYME (HALO) OSI (OSIP) Ridaforolimus Sanofi-Aventis (SAN) Prolor Biotech (PBTH) Sarepta (SRPT) Ariad (ARIA) Intermune (ITMN) CRISPR Therapeutics (CRSP) ADVENTRIX (ANX) ACADIA (ACAD) Multiple Myeloma Spike Therapeutics (ONCE) Aimmune Therapeutics (AIMT) Herceptin Genentech Sanofi (SNY) MODERNA ZALTRAP™ Telaprevir PORTOLA (PTLA) ImmunoGen (IMGN) Dynavax (DVAX) Micromet (MITI) Incyte (INCY) Alder Biopharmaceuticals (ALDR) AGOS (ARGS) Inovio (INO) Vertex (VRTX) NOVOCURE (NVCR) Bristol-Myers Squibb (BMY) JUNO (JUNO) Agenus (AGEN) JOUNCE THERAPEUTICS (JNCE) Xoma (XOMA) Advaxis (ADXS) TOKAI (TKAOI) Intercept (ICPT) Human Longevity (HLI) Editas (EDIT) Galena (GALE) BIOMARIN (BMRN) Array Pharmaceuticals (ARRY) Ionis (IONS) GUARDIAN HEALTH